Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Varsha Gandhi, PhD, on Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Jul
15
Today In Oncology
Gedatolisib Combinations Approved by FDA for HR-Positive/HER2-Negative Breast Cancer
FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors
American Cancer Society Reports Latest Global Cancer Statistics
Setmelanotide in Patients With Acquired Hypothalamic Obesity From Brain Tumors
Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo